Dysregulated bone morphogenetic proteins (BMPs) may contribute to the development and progression of renal cell carcinoma (RCC). Herein, we report that BMP-6 promotes the growth of RCC by IL-10-mediated M2 polarization of tumor-associated macrophages (TAMs). BMP-6-mediated IL-10 expression in macrophages required Smad5 and STAT3. In human RCC specimens, the three-marker signature BMP-6/IL-10/CD68 was associated with a poor prognosis.
INTRODUCTION
Kidney cancer is the seventh most common cancer with an estimated 58,240 new cases and 13,040 deaths in 2010 (1) . Histologically, the most common type of kidney cancer is clear cell renal cell carcinoma (RCC) (80-85%) (2) . As with most solid malignancies, localized RCC are usually cured with surgery. However, approximately 30% of patients with clinically localized RCC eventually recur after resection.
Bone morphogenetic proteins (BMPs) comprise the largest family within the transforming growth factor-beta (TGF-β) superfamily. Although originally reported as factors that induce bone and cartilage formation (3), BMPs have been shown to be critical for development (4) (5) (6) . More recently, we and others have reported that BMPs regulate the immune system as BMP-6 inhibits B and T cell proliferation (7, 8) and activates macrophages (9, 10) . In the context of RCC, BMP-4, -6, and -7 are often overexpressed (11, 12) while BMP antagonist Sclerostin domain-containing-1 (SOSTDC1) is down-regulated (13) . At the same time, we have observed that human RCC cells frequently have a loss of expression of BMP receptors (11) , suggesting a paracrine role for BMP-6 in RCC.
Macrophages are an essential component of the host defense system and have critical roles in both innate and adaptive immune responses (14) . In solid malignancies, a large number of macrophages is usually found infiltrating the tumor. These tumor-associated macrophages (TAMs) (15, 16) are recruited from the circulating peripheral blood monocytes by chemotactic factors and chemokines (17, 18) . When tumor cells arise, macrophages are capable of mounting an anti-tumor response (19). However, the decision to mount an anti-tumor response is in part regulated by the balance of pro-and anti-inflammatory factors present within the tumor microenvironment (14, 20) . Indeed, a body of evidence suggests that macrophages in tumors can promote cancer progression and metastasis by stimulating angiogenesis, tumor growth, and cellular migration and invasion (21).
One cytokine that has been suggested to play a role in regulating macrophages is interleukin-10 (IL-10), a type 2 cytokine. IL-10 is produced by monocytes, activated macrophages, and a subtype of dendritic cells (22) . In cancers, additional sources of IL-10 include the alternatively activated M2 macrophages and TAMs (23, 24). Since, the major stimulus for the IL-10 expression is inflammation, IL-10 plays a major role in the negative feedback loop that prevents uncontrolled inflammation (25). In solid tumors, IL-10 has been Author Manuscript Published OnlineFirst on April 30, 2013; DOI: 10.1158/0008-5472. detected in a number of malignancies (26). Recently, it has been suggested that a local production of IL-10 results in a tumor microenvironment that favors cancer cell survival and metastases (23, 27) . In RCC, IL-10 and IL-10 receptor expression has been correlated with increased incidence of metastasis (28). Nevertheless, the clinical significance of IL-10 and the mechanism of its induction in cancers remain largely unknown. In this study, we report that BMP-6 in murine RCC cell lines is pro-tumorigenic and involves IL-10-mediated M2 polarization of TAMs.
MATERIALS AND METHODS

Animal Studies
Balb/c and IL-10KO mice (Jackson Laboratory, Bar Harbor, ME) were inoculated subcutaneously with BMP-6/RenCa and BMP-6/RAG cells. For BMP-6 induction, drinking water containing 2 mg/ml of doxycycline (Sigma-Aldrich, St. Louis, MO) in 5% sucrose was used. For adoptive transfer of macrophages, 5x 10 6 cells were injected directly into tumors.
Unless indicated, 5 animals were used per group.
Cell culture RAW 264.7, RenCa, and RAG were purchased from the American Type Culture Collection (ATCC) (Manassas, VA) and routinely maintained in as recommended by the vendor. To obtain murine peritoneal macrophages (PM s), thioglycollate (Sigma-Aldrich, St. Louis, MO) was dissolved in dH 2 O and injected intraperitoneally into mice. Animals were sacrificed 3 days later and PM s were isolated from the peritoneal lavage and cultured as described (29). Primary human peripheral blood monocytes (hPBMC) were purchased from STEMCELL Technologies, Inc (Vancouver, Canada). The STAT3 inhibitor WP1066 (EMD Chemicals, Gibbstown, NJ) was used at 10 μg/ml. BMP-6 was obtained from R&D Systems (Minneapolis, MN).
BMP-6 inducible murine renal cell carcinoma cell lines
Research. Human BMP-6 cDNA was cloned into the tetracycline inducible vector pLenti4/Dest (Invitrogen). Simultaneously, RenCa and RAG were infected sequentially with the Tetracycline Repressor (TR) virus followed by pLenti4/BMP-6 virus.
RT-PCR
Total RNA was extracted with Trizol (Invitrogen, Carlsbad, CA) and RT-PCR was carried out using the One-step SuperScript RT-PCR® kit (Invitrogen). Reverse transcription was completed as recommended. For all primers, the annealing temperature was 55°C. Primer sequences are shown in Supp Table 1 .
Immunoblot
Cells were harvested using the Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA).
After centrifugation, electrophoresis was carried out with 30 μg of protein using 12% SDS-PAGE gel and analyzed using enhanced chemiluminescence (Thermo Scientific, Rockford, IL).
Antibodies
The following antibodies were used in this study: mouse IL-10 (VWR), human IL-10 (R&D Systems), β-actin (Sigma), human BMP-6 blocking antibody (R&D), human BMP-6 (Abcam), 
Luciferase assay
Luciferase assay was performed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) per manufacturer's protocol. Cells were transfected using lipofectamine 2000 (Invitrogen, Carlsbad, CA). All experiments were repeated at least 3 times.
Transient transfection of BMP receptors
RAW 264.7 cells were plated onto 6-well plates and lipofectamine 2000 (Invitrogen) at 1 μl/ml was used to transfect 1 μg/ml of plasmids.
Research. 
RNA knock-down studies
Sequences of shRNA and construction of expression system have previously been published (9, 29) . Knock-down of STAT3 and STAT4 was carried out using siRNA (Qiagen).
Chromatin Immunoprecipitation (ChIP) Assay
EZ-ChIP kit (Millipore) was used. Cells were harvested, fixed, and incubated with the indicated antibodies. Then DNA was sonicated and purified with spin column and analyzed with PCR.
Immunoprecipitation and Immunoblot
NE-PER (Thermo Scientific, Rockford, IL) was used to separate cytoplasmic and nuclear proteins. After pre-clearing with protein A sepharose (GE healthcare), indicated primary antibody was added to the lysate and incubated at 4 o C. Antibody was pulled down with protein A sepharose and washed with ice-cold lysis buffer and proteins were analyzed by immunoblot analysis.
ELISA
IL-10 and BMP-6 levels in the culture media and serum were measured using an ELISA kit (R&D Systems). The indicated values represent the average of 4 separate measurements.
Clodronate Liposome
Clodronate-and PBS-loaded liposomes were kindly provided by Clodronate Liposomes.org (Amsterdam, Netherlands). Mice were injected with 0.2 ml of either clodronate-liposomes (final dose of 25 mg/kg) or PBS-liposomes every 4 days intraperitoneally or intratumorally.
Human RCC tissues, serum, immunohistochemistry, and confocal microscopy
Seventy-four formalin-fixed paraffin-embedded human RCC tissues were obtained from Chungbuk National University (Cheongju, Korea) while human clear cell RCC tissue array containing 50 cases were purchased from Imgenex (San Diego, CA). Serum samples were available in 56 of the patients from Chungbuk National University. The sections were processed using a routine laboratory procedure and counterstained with hematoxylin. The results were interpreted by 2 independent investigators who were blinded to each other's reading.
Statistical analysis
Student's t test and Pearson correlation were performed. Clinical data were evaluated using Kaplan-Meier and multivariate Cox analysis. P-value <0.05 was considered statistically significant.
RESULTS
BMP-6 is pro-tumorigenic in RCC cells
Since published studies have suggested the dysregulation of BMPs in RCC (11, 13) , tetracycline inducible human BMP-6 expression system based on lentivirus was established in a murine RCC cell line, RenCa. Human BMP-6 cDNA was chosen to track the expression of exogenous BMP-6.
Previously, the use of human BMP-6 in mouse has been validated (9, 29) . Because RenCa cells were originally derived from Balb/c mice, syngeneic tumors can be established in immunecompetent animals. A representative result demonstrating the inducibility of BMP-6 mRNA and protein by tetracycline is shown in Fig 1A and 1B . One clone with a relatively high inducible level of BMP-6 was designated as RenCa/BMP-6. When BMP-6 expression was induced in RenCa/BMP-6 in tissue culture (Tet+), no significant effect on cellular proliferation was observed ( Fig 1C) . However, in Balb/c mice, the induction of BMP-6 (doxy+) demonstrated a significantly faster tumor growth without a noticeable change in histopathology (Fig 1D) . This pro-tumorigenic effect of BMP-6 only in vivo implicates a paracrine mechanism. Along this line, it has recently been reported that BMPs regulate immune effector cells including macrophages (9, 10) . To investigate whether macrophages mediate the pro-tumorigenic effect of BMP-6 in RCC, clodronate-liposome was used to selectively remove macrophages (30). The efficacy of clodronate-liposome in removing macrophages was confirmed in RenCa/BMP-6 syngeneic tumor model (Supp Fig 1A and B) . As predicted, BMP-6's pro-tumorigenic effect was completely blocked with clodronate-liposome (Fig 1E) . In these tumors, clodronate-liposome had no effect on BMP-6 induction by doxycycline (Supp Fig 1C) .
Next, the identical tetracycline-inducible BMP-6 system was developed in another murine kidney cancer cell line, RAG. The best clone with inducible BMP-6 expression was designated RAG/BMP-6. When RAG/BMP-6 was inoculated subcutaneously into Balb/c mice, induction of BMP-6 (doxy+) significantly enhanced tumor growth (Supp Fig 2) . Furthermore, clodronate-liposome injection reversed the oncogenic effect of BMP-6. These results collectively suggest that BMP-6's pro-tumorigenic activity requires macrophages.
Macrophages mediate the pro-tumorigenic effect of BMP-6 via IL-10
When the murine macrophage cell line RAW 264.7 was treated with BMP-6, multiplex PCR revealed that BMP-6 upregulated the expression of a number of cytokines including IL-10. When RAW 264.7, murine peritoneal macrophages (PM s), THP-1 (human monocyte cell line), and human peripheral blood monocytes (hPBMC) were treated with BMP-6, IL-10 mRNA and protein were induced in a concentration-and time-dependent manner (Fig 2A and B) ; quantitative RT-PCR in RAW 264.7 is shown in Supp Fig 3A. IL-10 mRNA induction by BMP-6 was detected as early as 1 hour and peaked at 24 hours in PM s. ELISA revealed that the concentration of IL-10 in the conditioned media exceeded 120 pg/ml when RAW 264.7 was treated with 100 ng/ml BMP-6 (Supp Fig 3B) . This level of secreted IL-10 was comparable to that when macrophages were stimulated with lipopolysaccharide (LPS). These observations suggest that BMP-6 induces local inflammation and tumor rejection in the absence of IL-10.
BMP-6 induces IL-10 expression in macrophages via BMP-RII and ALK2/3
To determine the mechanism of IL-10 induction by BMP-6, we used the transcription inhibitor actinomycin D (ActD) and the translation inhibitor cycloheximide (CHX). IL-10 induction was blocked only by ActD in both RAW 264.7 and PM s (Fig 3A) . In order to expedite the dissection of the signaling pathway involved in BMP-6-induced IL-10 expression, we next constructed a luciferase reporter vector containing the IL-10 promoter (IL10-Luc). When IL10-Luc was transiently transfected into RAW 264.7, BMP-6 increased luciferase activity approximately 2.5-fold within 6 hrs (Supp Fig 3C) .
BMPs signal through a heteromeric complex of types I and II receptors. When each of the three known BMP type II receptors were co-transfected with IL10-Luc into RAW 264.7, only BMP-RII overexpression increased IL-10 promoter activity upon treatment with BMP-6 ( Fig 3B) .
Conversely, knock-down experiments using short hairpin RNA (shRNA) (9) demonstrated the suppression of luciferase activity only when BMP-RII was targeted (Fig 3C) . To identify the functional BMP type I receptor(s), constitutively active mutant constructs were used.
Macrophages express only two of the three known BMP type I receptors -ALK2 and 3 (9).
Overexpression of constitutively active ALK2 and 3 (CA-ALK2 and CA-ALK3, respectively) increased the luciferase activity more than 10-fold ( Fig 3D) . When ALK2 and 3 were knocked down using shRNA (9), BMP-6 no longer induced luciferase activity (Fig 3E) . These results collectively suggest that BMP-RII along with ALK2 and 3 are the functional BMP-6 receptors that mediate IL-10 induction in macrophages.
IL-10 induction requires Smad5
Following the activation of receptors, the canonical BMP signaling requires receptor-mediated Smads (R-Smads) (Smad1, 5, and 8) and co-Smad (Smad4). When the Smad-dependent pathway was blocked in RAW 264.7 with dominant negative Smad4 (Smad4DN), IL-10 induction by BMP-6 was completely blocked (Fig 4A) . When each of the R-Smads was overexpressed in RAW 264.7, only Smad5 transfection increased luciferase activity upon treatment with BMP-6 ( Fig 4B) . This activation of IL-10 promoter by BMP-6 was then blocked when Smad5 was knocked down using shRNA ( Fig 4C) (29). Serial deletion of IL-10 promoter subsequently demonstrated that the BMP-6 response element within IL-10 promoter is located between 588 and 800 bp 5' to the transcription start site (Fig 4D) . ChIP analysis revealed that Smad5 bound to the -588 to -800 region of IL-10 promoter (Fig. 4E ).
STAT3 is required for IL-10 induction
Research. Fig 5B) . Next, studies using dominant negative STAT3 (STAT3DN) and small interfering RNA (siSTAT3) also demonstrated a complete abrogation of IL-10 induction by BMP-6 in RAW 264.7 ( Fig 5C, Supp Fig 4A) . When RAW 264.7 was transiently transfected with siSTAT3 and IL10-Luc, BMP-6 no longer increased luciferase activity (Supp Fig 4B) . The complementary experiment in which STAT3 and IL10-Luc were overexpressed in RAW 264.7, BMP-6 increased the luciferase activity significantly (Fig 5D) . Surprisingly, overexpression of STAT4 repeatedly blocked the activation of IL-10 promoter by BMP-6.
Next, ChIP assay demonstrated that STAT3 bound to the -588 to -800 bp region of IL-10 promoter (Fig. 5E ). Since Smad5 also bound to the same region, we subsequently tested whether STAT3 interacts with Smad 5. When each of the myc-tagged R-Smads was expressed in RAW 264.7, immunoprecipitation against endogenous STAT3 pulled down Smad5 while immunoprecipitation against myc-Smad5 precipitated out STAT3 (Supp Fig 4C) . The physical interaction between endogenous Smad5 and STAT3 in macrophages when stimulated by BMP-6 was then confirmed (Fig 5F) .
Consistent with the known functions of Smad5 and STAT3, confocal immunofluorescence microscopy showed that both STAT3 and Smad5 translocate to the nucleus of RAW 264.7 when treated with BMP-6 (Supp Fig 4D) . This BMP-6-induced nuclear translocation of STAT3 was still detected in RAW 264.7 even when Smad5 was knocked down (Supp Fig 4E) . The reverse experiment revealed that the nuclear translocation of Smad5 still occurred when STAT3 was knocked down (Supp Fig 4F) . Subsequently, co-immunoprecipitation of STAT3 and Smad5 was observed only in the nuclear fraction (Fig 5G) . In the absence of exogenous BMP-6, low levels of STAT3 and Smad5 were co-immunoprecipitated out in RAW 264.7, likely suggesting a low basal level of expression of BMPs. In RenCa/BMP-6 tumors, immunoblot confirmed the presence of both phosphorylated STAT3 and Smad1/5 ( Fig 5H) . Subsequently, immunofluorescence microscopy demonstrated the co-localization of pSTAT3, pSmad1/5, and F4/80 (murine macrophages) (Fig 5I) .
Interestingly, the induction of BMP-6 demonstrated a significantly higher number of macrophages within the tumors. These results confirm that both Smad5 and STAT3 are phosphorylated in macrophages upon BMP-6 induction in vivo.
BMP-6 induces M2 macrophage polarization via IL-10
IL-10 induces M2 polarization of macrophages that leads to local immunosuppression (19).
When RAW 264.7 was co-cultured with RenCa, there was a ten-fold increase in M2 makerspositive (CD206+/CD163+) cells (3.8% vs 40%) (Fig 6A) . This increase in M2 polarization was partially reversed when RenCa/RAW 264.7 co-culture was treated with BMP-6 or IL-10 neutralizing antibodies (Fig 6A) . When RAW 264.7 and hPBMC were treated directly with 100 ng/ml of BMP-6 for 3 days, there was a 4-fold increase in M2 cells (0.8% vs 3.8% for RAW 264.7 and 3.8% vs 16.7% for hPBMC) (Fig 6B) . The induction of M2 polarization by BMP-6 was again partially inhibited by anti-IL-10 antibody.
Adoptive transfer of macrophages
Although BMP-6 activates macrophages and induces the expression of type 1 proinflammatory cytokines including IL-6 and IL-1β (29, 34). Results of the present study suggest that the immunosuppressive effect of IL-10 appears to overcome the pro-inflammatory effects of IL-6 and IL-1β and mediates the overriding biological effect of BMP-6 that results in tumor growth in RCC. Therefore the disruption of IL-10 production by macrophages in the context of BMP-6 may tip the balance of local immune response in favor of inflammation that may lead to the activation of host immune system and tumor regression. To investigate this possibility, we again utilized the RenCa/BMP-6 tumor model in Balb/c mice following macrophage depletion with intraperitoneal injection of clodronate-liposome (Fig 6C) . When wild type macrophages were adoptively transferred intratumorally, the induction of BMP-6 led to a dramatic increase in tumor growth. In contrast, the injection of IL-10KO macrophages not only blocked the pro-tumorigenic effect of BMP-6 but also decreased significantly the rate of tumor growth. The modest level of IL-10 detected in animals administered clodronate-liposome is likely due to the recovery of 
native macrophages by the end of the experiment. Hematoxylin staining demonstrated a dramatic increase in neutrophil infiltration and necrosis in tumors injected with IL-10KO macrophages (Fig 6D) .
Analysis in human clear cell RCC tissues
To determine the clinical relevance of the current findings, 124 human clear cell RCC tissues were examined. A typical example of positive immunohistochemistry for BMP-6, CD68, IL-10, and CD206 is shown in Fig 7A. Confocal immunofluorescence microscopy revealed that in samples that were BMP-6-positive, CD68, IL-10, and CD206 frequently co-localized (Fig 7B) .
When each marker was analyzed individually in the context of tumor stage, grade, and size, only CD68 and BMP-6 correlated with grade while BMP-6 was associated with stage (Supp Fig 5A) .
When cumulative survival rate was examined, higher tumor stage and grade were associated with poor prognosis (Supp Fig 5B and C) ; this confirms the validity of our samples. Subsequent analysis of the 4 markers failed to demonstrate any association with outcome (Supp Fig 5D) .
However, when each of the four markers were examined collectively or in various combinations, being positive for three markers -BMP-6, CD68, and IL-10 -was associated with decreased cumulative survival ( Fig 7C) ; CD206 status did not add any further prognostic value. Next, a multivariate Cox analysis demonstrated that the three-marker signature (BMP-6/CD68/IL-10)
was an independent predictor of cumulative survival (Supp Table 2 ). When ELISA was carried out with serum banked from 56 patients, BMP-6 levels were not high enough for detection.
However, IL-10 serum level above 1 pg/ml was associated with an increased incidence of metastasis over a 5-year period (Fig 7D) .
Taken together, we propose that clear cell RCC-derived BMP-6 stimulates the expression of the anti-inflammatory type 2 cytokine IL-10 in TAMs via a physical interaction between Smad5 and STAT3. IL-10, in turn, induces M2 polarization of TAMS and suppresses the local anti-tumor immune response (Fig 7E) .
DISCUSSION
Because many types of solid tumors have elevated expression levels of BMPs, it has been proposed that BMPs may be oncogenic (35). Consistent with this hypothesis, we have observed that the overexpression of BMP-6 has a pro-tumorigenic effect in two murine RCC cell lines.
Research. This oncogenic activity of BMP-6 though, was seen only in vivo, suggesting that BMP-6 stimulates RCC proliferation via a paracrine mechanism. Canonical BMP signaling requires a heterotetrameric complex of types I and II receptors.
To date, three each of types I and II receptors have been reported (37). Although these receptors are promiscuous, there is an optimal receptor combination for each BMP as it has been demonstrated that there are co-receptors that are relatively specific for BMP-2 and -4 (38). In the context of BMP-6/IL-10, BMP-RII along with ALK2 and 3 efficiently transduced BMP-6 signal.
Whether there is a BMP-6-specific co-receptor remains to be studied. it is likely that STAT3 interacts directly with the DNA while Smad5 is a co-factor for the transcriptional activation of IL-10 by BMP-6. Further studies are necessary to verify this concept.
In clear cell RCC patients, BMP-6, CD68, IL-10, and CD206 had no prognostic value individually. This observation is consistent with the report that BMP-6 in clear cell RCC tissues does not predict outcome (12) . Notwithstanding, patients who had the three-marker signature composed of BMP-6, CD68, and IL-10 were more likely to die from RCC. Interestingly though, CD206 (M2 macrophages) did not add any further prognostic value. This is likely due to colinearity as the presence of IL-10 and macrophages (CD68) were consistently associated with CD206. These observations suggest that BMP-6's effect in RCC is dictated by the tumor microenvironment and that IL-10 may be a surrogate marker of BMP-6's pro-tumorigenic effect.
Results of the present study implicate IL-10 as a new biomarker and a potential therapeutic target in RCC. Specifically, elevated serum levels of IL-10 were associated with increased risk of metastatic RCC. On the therapeutic front, an adoptive transfer of IL-10KO macrophages resulted in a dramatic tumor regression. Therefore, serum IL-10 levels may eventually be used to identify patients who are best candidates for targeting BMP-6/IL-10 loop.
We are planning to test this concept in clear cell RCC patients using AS101, a small molecule inhibitor of IL-10 (39). E. ChIP assay demonstrated that Smad5 bound to the -800 to -588 bp region of IL-10 promoter in a ligand-dependent manner. As a control, exon 3 of IL-10 gene was amplified. E. ChIP assay demonstrated that STAT3 bound to the BMP-6 responsive region (-800 to -588 bp) within the IL-10 promoter in RAW 264.7. As control, exon 3 of IL-10 gene was amplified. 
